Drug Profile
Naloxegol - AstraZeneca/Nektar Therapeutics
Alternative Names: AZ13337019 oxalate; MOVANTIK; Movantik; Moventig; Naloxegol oxalate; NKTR-118; NKTR-118 oxalate; PEG-naloxol; Pegylated naloxolLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Nektar Therapeutics
- Developer AstraZeneca; Daiichi Sankyo Company; Knight Therapeutics; Kyowa Kirin International; Nektar Therapeutics; RedHill Biopharma
- Class Gastrokinetics; Laxatives; Morphinans; Small molecules
- Mechanism of Action Opioid mu receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Constipation
Most Recent Events
- 02 Aug 2023 Kyowa Kirin enters deal to enter into a joint venture with Grunenthal for Naloxegol (Moventig®) for opioid-induced constipation
- 27 May 2022 Naloxegol is still in phase I KODIAK16 trial for Constipation in Spain and United Kingdom (PO) (NCT02099591)
- 23 Sep 2021 RedHill Biopharma, AstraZeneca AB and AstraZeneca Pharmaceuticals LP and Nektar Therapeutics have entered into a settlement and license agreement with Aurobindo Pharma USA, Inc. resolving their patent litigation in the U.S. in response to Aurobindo's ANDA seeking approval by the US FDA .